Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Insulin glargine; (Soliqua) subcutaneous injection

Initiation (new start) criteria: Non-formulary lixisenatide/glargine (Soliqua) will be covered on the benefit when the following criteria are met:

Must meet criteria for both individual agents lixisenatide and glargine.

Criteria for lixisenatide: • Diagnosis of Type 2 Mellitus • Intolerance to preferred GLP-1 agonists (Victoza) AND injectable (Ozempic) • No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) • No personal history of gastroparesis • On maximally tolerated dose (dose appropriate per renal function) or allergy or intolerance* to metformin (includes both metformin IR and XR) • And meets one of the following criteria: o Inadequate glycemic response on both basal and bolus insulin despite high dose requirements (total daily insulin dose of 1.5 units per kilogram of body weight or more OR greater than 200 units) OR o Has experienced recurrent nocturnal with basal insulin defined as: 3 or more episodes of nocturnal hypoglycemia (BG less than 70 mg/dL) over the preceding 30 days that persists despite basal insulin dose reduction (including decrease in NPH dose and subsequent switch to and dose adjustment of )

Criteria for insulin glargine • Use in patients with type 1 diabetes mellitus as basal insulin -OR- • Use in patients with any type of diabetes age 19 or younger -OR- • Patients with mellitus AND insulinopenia o Insulinopenia is defined as a fasting C-peptide level of less than or equal to 0.88 ng/mL with a concurrent glucose of 70-225 mg/dL o In those with renal insufficiency with a creatinine clearance less than or equal to 50 ml/minute, insulinopenia is defined as a C-peptide level of less than or equal to 1.6 ng/mL with a concurrent glucose of 70-225 mg/dL -OR- • Use in patients with type 2 diabetes mellitus that experience recurrent nocturnal hypoglycemia (low blood sugar at night) with bedtime NPH insulin dosing defined as:

kp.org

cps/awc Revised 9/9/21 Effective 11/4/21

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Insulin glargine; lixisenatide (Soliqua) subcutaneous injection

3 or more episodes of nocturnal CBG (capillary blood glucose at night) less than 70 over the preceding 30 days that persists despite NPH insulin dose reduction o For patients on 70/30 insulin, trial of NPH insulin (dosed am and bedtime) and (dosed breakfast and dinner) where the bedtime dose of NPH insulin resulted in recurrent hypoglycemia as defined above -OR- • Use in patients with type 2 diabetes mellitus on NPH insulin that experience any episode of severe hypoglycemia defined as: hypoglycemia resulting in seizures, loss of consciousness, episode necessitating assistance from someone else, EMT (emergency medical technician), and/or use of glucagon (medication used to raise the concentration of glucose in the blood) -OR- • Use in patient with type 2 diabetes mellitus that require ultra-long acting insulin due to work (night shift work where hours of sleep are significantly and repeatedly varied over time, frequent time-zone traveler)

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

kp.org

cps/awc Revised 9/9/21 Effective 11/4/21

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Insulin glargine; lixisenatide (Soliqua) subcutaneous injection

Criteria for members already taking the medication who have not been reviewed previously (e.g., new members): Non-formulary lixisenatide/glargine (Soliqua) will be covered on the prescription drug benefit when the following criteria are met:

Must meet criteria for both individual agents lixisenatide and insulin glargine.

Criteria for lixisenatide: • Diagnosis of Type 2 Diabetes Mellitus • Intolerance to preferred GLP-1 agonists liraglutide (Victoza) AND injectable semaglutide (Ozempic) • No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) • No personal history of gastroparesis • On maximally tolerated metformin dose (dose appropriate per renal function) or allergy or intolerance* to metformin (includes both metformin IR and XR) • And meets one of the following criteria: o Inadequate glycemic response on both basal and bolus insulin despite high dose requirements (total daily insulin dose of 1.5 units per kilogram of body weight or more OR greater than 200 units) OR o Has experienced recurrent nocturnal hypoglycemia with basal insulin defined as: 3 or more episodes of nocturnal hypoglycemia (BG less than 70 mg/dL) over the preceding 30 days that persists despite basal insulin dose reduction (including decrease in NPH dose and subsequent switch to and dose adjustment of insulin glargine)

Criteria for insulin glargine • Use in patients with type 1 diabetes mellitus as basal insulin OR • Use in patients with any type of diabetes age 19 or younger OR • Patients with Type 2 diabetes mellitus AND insulinopenia o Insulinopenia is defined as a fasting C-peptide level of less than or equal to 0.88 ng/mL with a concurrent glucose of 70-225 mg/dL o In those with renal insufficiency with a creatinine clearance less than or equal to 50 ml/minute, insulinopenia is defined as a C-peptide level of less than or equal to 1.6 ng/mL with a concurrent glucose of 70-225 mg/dL -OR- • Use in patients with type 2 diabetes mellitus that experience recurrent nocturnal hypoglycemia (low blood sugar at night) with bedtime NPH insulin dosing defined as:

kp.org

cps/awc Revised 9/9/21 Effective 11/4/21

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Insulin glargine; lixisenatide (Soliqua) subcutaneous injection

3 or more episodes of nocturnal CBG (capillary blood glucose at night) less than 70 over the preceding 30 days that persists despite NPH insulin dose reduction o For patients on 70/30 insulin, trial of NPH insulin (dosed am and bedtime) and Regular insulin (dosed breakfast and dinner) where the bedtime dose of NPH insulin resulted in recurrent hypoglycemia as defined above -OR- • Use in patients with type 2 diabetes mellitus on NPH insulin that experience any episode of severe hypoglycemia defined as: hypoglycemia resulting in seizures, loss of consciousness, episode necessitating assistance from someone else, EMT (emergency medical technician), and/or use of glucagon (medication used to raise the concentration of glucose in the blood) -OR- • Use in patient with type 2 diabetes mellitus that require ultra-long acting insulin due to work (night shift work where hours of sleep are significantly and repeatedly varied over time, frequent time-zone traveler)

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

kp.org

cps/awc Revised 9/9/21 Effective 11/4/21